WO1994017828A3 - Treatment for insulin dependent diabetes - Google Patents

Treatment for insulin dependent diabetes Download PDF

Info

Publication number
WO1994017828A3
WO1994017828A3 PCT/US1994/001456 US9401456W WO9417828A3 WO 1994017828 A3 WO1994017828 A3 WO 1994017828A3 US 9401456 W US9401456 W US 9401456W WO 9417828 A3 WO9417828 A3 WO 9417828A3
Authority
WO
WIPO (PCT)
Prior art keywords
insulin dependent
treatment
dependent diabetes
diabetes
vla4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1994/001456
Other languages
French (fr)
Other versions
WO1994017828A2 (en
Inventor
Linda C Burkly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21848497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1994017828(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AU62379/94A priority Critical patent/AU687790B2/en
Application filed by Biogen Inc filed Critical Biogen Inc
Priority to ES94909584T priority patent/ES2114183T5/en
Priority to DE69407758T priority patent/DE69407758T3/en
Priority to CA2155303A priority patent/CA2155303C/en
Priority to HK98108899A priority patent/HK1008731A1/en
Priority to JP51833394A priority patent/JP3593343B2/en
Priority to EP94909584A priority patent/EP0682529B2/en
Priority to DK94909584T priority patent/DK0682529T4/en
Publication of WO1994017828A2 publication Critical patent/WO1994017828A2/en
Publication of WO1994017828A3 publication Critical patent/WO1994017828A3/en
Anticipated expiration legal-status Critical
Priority to GR980400715T priority patent/GR3026531T3/en
Priority to US11/103,362 priority patent/US20050208053A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70542—CD106
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

A method for the prevention of insulin dependent (type I) diabetes. The method comprises administration of an antibody, polypeptide or other molecule recognizing VLA4.
PCT/US1994/001456 1993-02-09 1994-02-09 Treatment for insulin dependent diabetes Ceased WO1994017828A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EP94909584A EP0682529B2 (en) 1993-02-09 1994-02-09 Antibody for the treatment of insulin dependent diabetes
JP51833394A JP3593343B2 (en) 1993-02-09 1994-02-09 Treatment of insulin-dependent diabetes
ES94909584T ES2114183T5 (en) 1993-02-09 1994-02-09 ANTIBODY FOR THE TREATMENT OF INSULIN DEPENDENT DIABETES.
DE69407758T DE69407758T3 (en) 1993-02-09 1994-02-09 ANTIBODIES FOR THE TREATMENT OF INSULIN-DEPENDENT DIABETES
CA2155303A CA2155303C (en) 1993-02-09 1994-02-09 Treatment for insulin dependent diabetes
HK98108899A HK1008731A1 (en) 1993-02-09 1994-02-09 Antibody for the treatment of insulin dependent diabetes
DK94909584T DK0682529T4 (en) 1993-02-09 1994-02-09 Antibody for the treatment of insulin-requiring diabetes
AU62379/94A AU687790B2 (en) 1993-02-09 1994-02-09 Treatment for insulin dependent diabetes
GR980400715T GR3026531T3 (en) 1993-02-09 1998-04-03 Treatment for insulin dependent diabetes.
US11/103,362 US20050208053A1 (en) 1993-02-09 2005-04-11 Treatment for insulin dependent diabetes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2933093A 1993-02-09 1993-02-09
US08/029,330 1993-02-09

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US08/447,118 Continuation-In-Part US5888507A (en) 1993-02-09 1995-05-22 Treatment for insulin dependent diabetes

Publications (2)

Publication Number Publication Date
WO1994017828A2 WO1994017828A2 (en) 1994-08-18
WO1994017828A3 true WO1994017828A3 (en) 1994-10-13

Family

ID=21848497

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/001456 Ceased WO1994017828A2 (en) 1993-02-09 1994-02-09 Treatment for insulin dependent diabetes

Country Status (13)

Country Link
US (2) US5888507A (en)
EP (1) EP0682529B2 (en)
JP (1) JP3593343B2 (en)
AT (1) ATE161730T1 (en)
AU (1) AU687790B2 (en)
CA (1) CA2155303C (en)
DE (1) DE69407758T3 (en)
DK (1) DK0682529T4 (en)
ES (1) ES2114183T5 (en)
GR (1) GR3026531T3 (en)
HK (1) HK1008731A1 (en)
NZ (1) NZ262615A (en)
WO (1) WO1994017828A2 (en)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0670735T3 (en) 1992-11-13 1997-07-28 Univ Washington Peripheral Hematopoietic Stem Cells.
DK0678122T3 (en) 1993-01-12 2000-03-06 Biogen Inc Recombinant anti-VLA4 antibody molecules
WO1994017828A2 (en) * 1993-02-09 1994-08-18 Biogen, Inc. Treatment for insulin dependent diabetes
US5677291A (en) * 1993-12-10 1997-10-14 Hoechst Marion Roussel, Inc. Method of lowering serum cholesterol levels with 2,6-di-alkyl-4-silyl-phenols
US5750336A (en) * 1994-02-10 1998-05-12 The Salk Institute For Biological Studies Assays for the identification of compounds which inhibit activation of cAMP and mitogen responsive genes
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US5795876A (en) * 1996-04-30 1998-08-18 Hoechst Marion Rousssel, Inc. Method of inhibiting vascular cell adhesion molecule-1 and treating chronic inflammatory diseases with 2, 6-di-alkyl-4-silyl-phenols
US5608095A (en) * 1996-04-30 1997-03-04 Hoechst Marion Roussel, Inc. Alkyl-4-silyl-phenols and esters thereof as antiatherosclerotic agents
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US6114572A (en) * 1996-11-20 2000-09-05 Hoechst Marion Roussel, Inc. Substituted phenols and thiophenols useful as antioxidant agents
JP2001515360A (en) * 1997-04-18 2001-09-18 バイオジェン，インコーポレイテッド Type II TGF-β receptor / immunoglobulin constant region fusion protein
US6121463A (en) * 1997-06-24 2000-09-19 Hoechst Marion Roussel, Inc. Alkyl-4-silylheterocyclic phenols and thiophenols useful as antioxidant agents
US6133467A (en) * 1997-06-25 2000-10-17 Hoechst Marion Roussel, Inc. 2,6-di-t-butyl-4-[(dimethyl-4-methoxyphenylsilyl)-methyl-oxy]phenol and 2,6-di-t-butyl-4-[(dimethyl-2-methoxy-phenylsilyl)methyloxy]phenol
DE19741235A1 (en) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Novel imidazolidine derivatives, their preparation, their use and pharmaceutical compositions containing them
DE19741873A1 (en) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh New 5-ring heterocycles, their preparation, their use and pharmaceutical preparations containing them
DE19751251A1 (en) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituted imidazolidine derivatives, their manufacture, their use and pharmaceutical preparations containing them
DE19821483A1 (en) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh New imidazolidine derivatives useful as leukocyte adhesion and migration inhibitors and/or VLA-4 receptor antagonists for treating E.G. inflammatory and allergic disorders
EP2065050A1 (en) 1998-09-14 2009-06-03 Board of Regents, The University of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
US6110109A (en) * 1999-03-26 2000-08-29 Biosignia, Inc. System and method for predicting disease onset
CN1332714C (en) 1999-04-22 2007-08-22 比奥根艾迪克Ma公司 Method for treating fibrosis by utilizing integrin alpha 4 subunit antagonist
DE19922462A1 (en) 1999-05-17 2000-11-23 Aventis Pharma Gmbh New phenylureidobenzyl-substituted spiro-imidazolidinedione derivatives, are inhibitors of leukocyte adhesion or migration or VLA-4 receptors, useful e.g. for treating inflammatory or allergic disease
IL146508A0 (en) 1999-06-01 2002-07-25 Biogen Inc A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders
ES2263485T3 (en) * 1999-09-14 2006-12-16 Biogen Idec Ma Inc. THERAPY FOR CHRONIC RENAL INSUFFICIENCY USING ONE OR MORE INTEGRIN ANGTAGONISTS.
US20010046489A1 (en) 1999-12-06 2001-11-29 Habener Joel E. Stem cells of the islets of langerhans and their use in treating diabetes mellitus
JP2003517023A (en) 1999-12-16 2003-05-20 バイオジェン インコーポレイテッド Method of treating ischemic or hemorrhagic damage of the central nervous system with an anti-α4 integrin antagonist
US20060115473A1 (en) * 2000-12-14 2006-06-01 Biogen Idec Ma Inc., A Massachusetts Corporation Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
JP3459609B2 (en) * 2000-03-17 2003-10-20 三洋電機株式会社 Write cache circuit, recording device provided with write cache circuit, and write cache method
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
DE10111877A1 (en) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Novel imidazolidine derivatives, their preparation, their use and pharmaceutical compositions containing them
GEP20074252B (en) 2001-04-13 2007-12-10 Biogen Idec Inc Antibodies to vla-1
DE10137595A1 (en) 2001-08-01 2003-02-13 Aventis Pharma Gmbh New 3-alkylaminoalkyl-imdazolidin-4-one derivatives, are VLA-4 receptor and leukocyte adhesion and/or migration inhibitors, useful e.g. for treating inflammatory, allergic, autoimmune or cardiovascular disease
FR2849598B1 (en) * 2003-01-07 2006-09-22 Merck Sante Sas USE OF KYNURENINE-3-HYDROXYLASE INHIBITORS FOR THE TREATMENT OF DIABETES BY INCREASING THE NUMBER OF CELLS OF THE LANGERHANS ISLANDS
CA2514125A1 (en) 2003-01-24 2004-08-12 Elan Pharmaceuticals, Inc. Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
US7419666B1 (en) 2004-02-23 2008-09-02 Massachusetts Eye And Ear Infirmary Treatment of ocular disorders
CA2478458A1 (en) 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
CN103169965A (en) 2004-11-19 2013-06-26 比奥根艾迪克Ma公司 Treatment for multiple sclerosis
EP1833509A4 (en) * 2004-12-03 2008-12-03 Biogen Idec Inc Delaying or preventing onset of multiple sclerosis
EP3796003A1 (en) 2005-04-04 2021-03-24 Biogen MA Inc. Methods for evaluating an immune response to a therapeutic agent
JP2009515552A (en) * 2005-11-17 2009-04-16 ミレニアム・ファーマシューティカルズ・インコーポレイテッド α4β7 integrin-reactive humanized immunoglobulin
MX2008014793A (en) 2006-05-25 2008-12-02 Biogen Idec Inc Methods of treating stroke.
EP2170390B1 (en) * 2007-06-14 2018-11-07 Biogen MA Inc. Natalizumab antibody formulations
ES2824261T3 (en) 2007-09-14 2021-05-11 Biogen Ma Inc Compositions and procedures for the treatment of progressive multifocal leukoencephalopathy (PML)
DK2982695T3 (en) 2008-07-09 2019-05-13 Biogen Ma Inc COMPOSITIONS CONCERNING ANTIBODIES AGAINST LINGO OR FRAGMENTS THEREOF
BRPI1011389A2 (en) * 2009-04-17 2018-07-10 Biogen Idec Inc method for treating acute myelogenous leukemia (aml) in a patient
WO2011020874A1 (en) 2009-08-20 2011-02-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
EP2485762B1 (en) 2009-10-11 2017-12-13 Biogen MA Inc. Anti-vla-4 related assays
SMT202000306T1 (en) 2010-04-16 2020-07-08 Biogen Ma Inc Anti-vla-4 antibodies
HUE050713T2 (en) 2010-10-25 2020-12-28 Biogen Ma Inc Methods for determining differences in alpha-4 integrin activity by correlating differences in svcam and/or smadcam levels
DK3311834T3 (en) 2011-05-02 2026-04-20 Millennium Pharmaceuticals Inc ANTI-ALPHA4BETA7 ANTIBODY FORMULATION
UA116189C2 (en) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. COMPOSITION OF ANTI-α4β7 ANTIBODY
CA2864539C (en) 2012-02-16 2022-06-07 Santarus, Inc. Antibody formulations
DK2828284T3 (en) 2012-03-20 2019-06-11 Biogen Ma Inc JCV NEUTRALIZING ANTIBODIES
EP2845134A1 (en) 2012-04-20 2015-03-11 Biogen Idec MA Inc. Cognitive composite parameters and uses thereof for evaluating multiple sclerosis
CN104470541A (en) 2012-05-14 2015-03-25 比奥根艾迪克Ma公司 Lingo-2 antagonists for treatment of conditions involving motor neurons
US8735359B2 (en) * 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
WO2014028299A1 (en) 2012-08-13 2014-02-20 Biogen Idec Ma Inc. Disease progression parameters and uses thereof for evaluating multiple sclerosis
JP2015534564A (en) 2012-10-09 2015-12-03 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Combination therapy and use for the treatment of demyelinating disorders
WO2015063604A2 (en) 2013-11-01 2015-05-07 Imberti Luisa BIOMARKERS PREDICTIVE OF THERAPEUTIC RESPONSIVENESS TO IFNβ AND USES THEREOF
JP2018504400A (en) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． LINGO-1 antagonist and use for treatment of demyelinating disorders
AU2016270373A1 (en) 2015-06-05 2018-01-04 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
JP7149257B2 (en) 2016-07-13 2022-10-06 バイオジェン・エムエイ・インコーポレイテッド LINGO-1 Antagonist Dosing Regimens and Uses for Treatment of Demyelinating Disorders
WO2018045162A1 (en) 2016-09-01 2018-03-08 Biogen Ma Inc. Biomarkers predictive of primary progressive multiple sclerosis and uses thereof
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018140510A1 (en) 2017-01-25 2018-08-02 Biogen Ma Inc. Compositions and methods for treatment of stroke and other cns disorders
US12037398B2 (en) 2018-06-04 2024-07-16 Biogen Ma Inc. Anti-VLA-4 antibodies having reduced effector function
BR112021017644A2 (en) 2019-03-11 2021-11-16 Biogen Ma Inc Pharmaceutical compositions containing anti-lingo-1 antibodies
US20240301512A1 (en) 2021-01-29 2024-09-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists
TW202411250A (en) * 2022-05-24 2024-03-16 美商預防生物股份有限公司 Methods and compositions for preventing or delaying type 1 diabetes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993008823A1 (en) * 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
WO1993013798A1 (en) * 1992-01-13 1993-07-22 Biogen, Inc. Treatment for asthma
WO1993015764A1 (en) * 1992-02-12 1993-08-19 Biogen, Inc. Treatment for inflammatory bowel disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ215865A (en) * 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
US5053393A (en) * 1988-07-20 1991-10-01 Monsanto Company Novel platelet-aggregation inhibitor
US4879313A (en) * 1988-07-20 1989-11-07 Mosanto Company Novel platelet-aggregation inhibitors
ATE142505T1 (en) * 1988-11-14 1996-09-15 Brigham & Womens Hospital ANTIBODIES SPECIFIC TO ELAM-1 AND THEIR USE
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
US5217870A (en) * 1989-04-28 1993-06-08 Biogen, Inc. Monoclonal antibodies against CDX
US5061693A (en) * 1989-07-28 1991-10-29 Merck & Co., Inc. Fibrinogen receptor antagonists
IL113261A (en) † 1989-09-01 1996-10-16 Hutchinson Fred Cancer Res Inhibition by peptides of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction and pharmaceutical compositions containing said peptides
US4952562A (en) * 1989-09-29 1990-08-28 Rorer Pharmaceutical Corporation Anti-thrombotic peptides and pseudopeptides
US5053392A (en) * 1989-12-01 1991-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Novel arginine, glycine, aspartic acid derivatives as platelet-aggregation inhibitors
US5260277A (en) * 1990-09-10 1993-11-09 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
DK0670735T3 (en) * 1992-11-13 1997-07-28 Univ Washington Peripheral Hematopoietic Stem Cells.
US5591719A (en) * 1992-12-10 1997-01-07 Regents Of The University Of Minnesota Method for treating acute and chronic inflammatory disorders using polypeptides with fibronectin activity
DK0678122T3 (en) * 1993-01-12 2000-03-06 Biogen Inc Recombinant anti-VLA4 antibody molecules
WO1994017828A2 (en) * 1993-02-09 1994-08-18 Biogen, Inc. Treatment for insulin dependent diabetes
EP0804237B8 (en) * 1994-01-25 2006-11-08 Elan Pharmaceuticals, Inc. Humanized antibodies against leukocyte adhesion molecule vla-4

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993008823A1 (en) * 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
WO1993013798A1 (en) * 1992-01-13 1993-07-22 Biogen, Inc. Treatment for asthma
WO1993015764A1 (en) * 1992-02-12 1993-08-19 Biogen, Inc. Treatment for inflammatory bowel disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
C. DOSQUET ET AL.: "Molecular mechanism of blood monocyte adhesion to vascular endothelial cells.", NOUVELLE REVUE FRANÇAISE D'HÉMATOLOGIE, vol. 34, no. SUP., 1992, PARIS, FRANCE, pages S55 - S59 *
X. YANG ET AL.: "Inhibition of insulitis and prevention of diabetes in nonobese diabetic mice by blocking L-selectin and very late antigen 4 adhesion receptors.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 90, no. 22, 15 November 1943 (1943-11-15), WASHINGTON DC, USA, pages 10494 - 10498 *

Also Published As

Publication number Publication date
DK0682529T3 (en) 1998-09-07
ES2114183T3 (en) 1998-05-16
NZ262615A (en) 1996-02-27
DE69407758D1 (en) 1998-02-12
ATE161730T1 (en) 1998-01-15
DE69407758T3 (en) 2007-05-24
EP0682529A1 (en) 1995-11-22
JP3593343B2 (en) 2004-11-24
DE69407758T2 (en) 1998-08-27
AU687790B2 (en) 1998-03-05
HK1008731A1 (en) 1999-05-14
EP0682529B1 (en) 1998-01-07
CA2155303C (en) 2010-04-20
JPH08508719A (en) 1996-09-17
ES2114183T5 (en) 2006-06-16
GR3026531T3 (en) 1998-07-31
US5888507A (en) 1999-03-30
US20050208053A1 (en) 2005-09-22
AU6237994A (en) 1994-08-29
EP0682529B2 (en) 2005-12-28
WO1994017828A2 (en) 1994-08-18
CA2155303A1 (en) 1994-08-18
DK0682529T4 (en) 2006-05-15

Similar Documents

Publication Publication Date Title
WO1994017828A3 (en) Treatment for insulin dependent diabetes
GR3023203T3 (en) Treatment for asthma.
CA2115348A1 (en) Process for the production of pharmaceutical preparations containing human protein for infusion or injection purposes
EP0655702A3 (en) Stylus-input recognition correction manager.
EP1266965A3 (en) Recombinant antibodies for human therapy
EP1174135A3 (en) Pharmaceutical composition for use in treatment of diabetes
AU4355796A (en) Syringe, its sealing structure and sealing method and sliding valve for syringe
EP0664136A3 (en) Syringe assembly for lyophilizing, reconstituting and injecting a medication.
AU7025294A (en) Method for oscillometric blood pressure determination employing curve fitting
AU8163394A (en) Treatment of diabetes by administration of myo-inositol
AU1470292A (en) Stabilized factor viii preparations
AU609981B2 (en) Oil-in-water pesticidal emulsion, process for application
EP0632286A3 (en) Self-calibrating, eigenstructure based method and means of direction finding.
CA2222755A1 (en) Separation of hemoglobin on hydroxyapatite using hplc
WO1999033475A8 (en) Galactosylceramide, glucosylceramide, lactosylceramide, and specific catchers therefor for use in the prophylaxis or therapy of prediabetes, diabetes and/or associated complications
AU2415888A (en) A method for preventing blood coaguli from being formed in the extra-body circuit of dialysis apparatus and composition useful therefor
AU2930889A (en) Pharmaceutical preparation for treating immunodeficiency conditions
ZA964749B (en) Method for preparing N,N'disubstituted cyclic ureas.
EP0953355A4 (en) Remedy for autoimmune diseases
WO1999053064A3 (en) Methods of delivering glp-1
WO1998054724A3 (en) Web-based management of an enhanced services platform and method
AU3582593A (en) Antigen recognized by patients with antibody associated lambert-eaton myasthenic syndrome (LEMS), DNA encoding same and uses thereof
HUT71793A (en) 2,4-diamino-3-hydroxy-carboxylic acid derivatives, pharmaceutical compns. contg. them and process for producing the said compds.
WO1997024125A3 (en) Injectable pharmaceutical composition comprising ursodesoxycholic acid or tauroursodesoxycholic acid, a strong base and tromethamol
EP0235904A3 (en) Treatment of allergy with thymopentin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP NZ US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1994909584

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2155303

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 262615

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 1994909584

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1994909584

Country of ref document: EP